This is a working overview of Somatotroph, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2026-07-20 and is reviewed periodically as new material appears.
Whether the drug improves hard clinical outcomes is not settled. No completed trial has shown a reduction in heart attacks or strokes among treated patients, although a dedicated cardiovascular outcomes study has been discussed in the literature. Investigators have also examined hepatic fat in people with HIV and fatty liver disease, cognitive measures in small cohorts, and changes in bone density. Regulatory labeling emphasizes monitoring of insulin-like growth factor 1 because supraphysiologic levels raise questions about tissue growth, and the clinical significance of that signal remains an open question rather than a demonstrated harm.
Binding of tesamorelin to the growth hormone-releasing hormone receptor on anterior pituitary somatotrophs activates a Gs protein pathway, raises cyclic AMP, and triggers release of stored growth hormone into the bloodstream. Because the analogue resists dipeptidyl peptidase-4, its plasma residence time exceeds that of native GHRH, producing a larger and more sustained secretory signal. The released growth hormone then acts on the liver and peripheral tissues to raise insulin-like growth factor 1, which feeds back on the hypothalamus and pituitary. This axis explains both the intended effects on fat distribution and the biological markers used to track them.
Studies of the compound rely on imaging and laboratory endpoints rather than on symptoms alone. Visceral adipose tissue is usually quantified by computed tomography or magnetic resonance imaging at the level of the abdomen, with waist circumference serving as a cheaper but less specific proxy. Blood work tracks insulin-like growth factor 1, fasting glucose, glycated hemoglobin, and lipid fractions. In the pivotal trials the imaging endpoint fell by roughly fifteen to twenty percent over six months, subcutaneous fat changed little, and the visceral fat returned toward baseline after treatment stopped, a pattern that shapes how clinicians discuss durability.
A Phase 3 program led to regulatory approval in the United States in 2010 for reduction of excess visceral abdominal fat in adults with HIV and lipodystrophy. Subsequent studies examined effects on liver fat, muscle area, and metabolic markers, with mixed findings for some endpoints. Long-term cardiovascular outcomes and effects on mortality remain uncertain because most trials were relatively short and focused on imaging-based fat measurements. Use in populations without HIV has been studied experimentally but is not part of the approved indication.
Tesamorelin is a synthetic analog of growth hormone-releasing hormone, a peptide hormone produced by the hypothalamus. The molecule retains the 44-amino-acid sequence of human GHRH and carries a trans-3-hexenoyl modification at its N-terminus. This modification increases resistance to enzymatic degradation and extends the peptide's functional stability relative to native GHRH. The compound is supplied as a lyophilized powder for reconstitution and subcutaneous administration in clinical settings. Its development code was TH9507, and it belongs to the GHRH analog class. It is not a growth hormone product; instead, it acts upstream to stimulate endogenous growth hormone release.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Lyophilized cake in single-use vials |
| Solubility class | Freely soluble in water | Reconstituted with sterile diluent before injection |
| Typical storage temperature | 2 to 8 degrees Celsius | Before reconstitution; protect from light |
| Typical analytical method | Reversed-phase high-performance liquid chromatography | Purity and related-substance testing |
| Identity confirmation | Mass spectrometry | Observed mass near 5.1 kDa for the intact peptide |
Pharmacodynamic studies show that tesamorelin reduces visceral adipose tissue more than subcutaneous adipose tissue in the studied population. This selectivity may relate to differences in blood flow and hormone sensitivity between fat depots. Effects on glucose metabolism and insulin sensitivity have been investigated, with some trials reporting modest changes and others showing stability. The precise relationship between growth hormone exposure, IGF-1 levels, and visceral fat loss remains an active area of analysis.
Tesamorelin binds to growth hormone-releasing hormone receptors on somatotroph cells in the anterior pituitary. Receptor activation increases intracellular cyclic AMP and promotes synthesis and secretion of growth hormone. Because the peptide mimics endogenous GHRH, it amplifies the normal pulsatile release of growth hormone rather than providing exogenous growth hormone directly. This upstream action distinguishes tesamorelin from recombinant growth hormone preparations and from growth hormone secretagogues that act at different receptors.
Stimulated growth hormone release leads to hepatic production of insulin-like growth factor 1, a key mediator of many growth hormone effects. In clinical studies, tesamorelin increased IGF-1 levels in a dose-dependent manner, although the response varies among individuals. The drug's effect on visceral fat is thought to involve growth hormone-mediated lipolysis and altered adipocyte metabolism. Muscle mass and lean body mass have also been assessed as secondary outcomes, but changes are generally smaller and less consistent than fat reductions.
监管记录显示，特沙莫瑞林于 2010 年在美国首次获得批准，用于人类免疫缺陷病毒感染相关的脂肪营养不良患者。批准依据来自降低内脏脂肪的临床试验，而非体重或瘦体重的普遍改善。后续出现了不同制剂版本，但其核心适应症保持一致。关于长期心血管结局和死亡率影响，现有证据仍不充分。
在临床研究之外，特沙莫瑞林常被讨论为生长激素分泌促进剂，但这一说法需要限定。它并不等同于生长激素本身，也不属于普通减重药物。部分研究关注其减少腹部脂肪和改善脂质谱的潜力，另一些研究则关注胰岛素抵抗和 IGF-1 升高等信号。这些效应的临床意义仍在评估中，尚未形成统一结论。
特沙莫瑞林是一种合成肽，其序列与人生长激素释放激素的 44 个氨基酸形式相关。它在 N 端带有反式-3-己烯酰基修饰，这一改动可减缓二肽基肽酶 IV 的降解。该化合物属于生长激素释放激素受体激动剂，可刺激垂体释放生长激素。研究文献通常将其归入合成肽类药物，而非小分子化合物。
MRI uses powerful magnets and can therefore cause magnetic materials to move at great speeds, posing a projectile risk, and may cause fatal accidents. However, as millions of MRIs are performed globally each year, fatalities are extremely rare. MRI machines can produce loud noise, up to 120 dB(A). This can cause hearing loss, tinnitus and hyperacusis, so appropriate hearing protection is essential for anyone inside the MRI scanner room during the examination.
The Rhodesian army continued its "mobile counter-offensive" strategy of holding key positions ("vital asset ground") while carrying out raids into the no-go areas and into neighbouring countries. While often extraordinarily successful in inflicting heavy guerrilla casualties, such raids also on occasion failed to achieve their objectives. In April 1979 special forces carried out a raid on Joshua Nkomo's residence in Lusaka, Zambia, with the stated intention of assassinating him. Nkomo and his family left hastily a few hours before the raid – having clearly been warned that the raid was coming. In 1979, some special forces units were accused of using counterinsurgent operations as cover for ivory poaching and smuggling. Colonel Reid-Daly (commander of the Selous Scouts) discovered that his phone was bugged and after challenging a superior officer on this issue was court martialled for insubordination. He received the lightest sentence possible, a caution, but he continued to fight his conviction and eventually resigned his commission and left the Army. By 1978–1979, up to 70% of the regular army was composed of black soldiers (though both the army and police reserves remained overwhelmingly white). By 1979 there were also 30 black commissioned officers in the regular army. While there was never any suggestion of disloyalty among the soldiers from predominantly black units (in particular within the Selous Scouts or the Rhodesian African Rifles – RAR), some argue that, by the time of the 1980 election, many of the RAR soldiers voted for Robert Mugabe.
2 I− + 2 Fe3+ → I2 + 2 Fe2+ (E0 = +0.23 V) Ferric iodide, a black solid, is not stable in ordinary conditions, but can be prepared through the reaction of iron pentacarbonyl with iodine and carbon monoxide in the presence of hexane and light at the temperature of −20 °C, with oxygen and water excluded. Complexes of ferric iodide with some soft bases are known to be stable compounds.
== Clinical significance == Toxic vacuolation is associated with sepsis, particularly when accompanied by toxic granulation. The finding is also associated with bacterial infection, alcohol toxicity, liver failure, and treatment with granulocyte colony-stimulating factor, a cytokine drug used to increase the absolute neutrophil count in patients with neutropenia. The formation of toxic vacuoles represents increased phagocytic activity, which is stimulated by the release of cytokines in response to inflammation or tissue injury. Toxic vacuolation frequently occurs in conjunction with toxic granulation and Döhle bodies in inflammatory states, and these findings are collectively referred to as toxic changes. Neutrophilia and left shift (the presence of immature neutrophil precursors such as band neutrophils and metamyelocytes in the peripheral blood) often accompany toxic changes, as these phenomena also occur in response to inflammation. It has been suggested that neutrophil vacuoles not be labelled "toxic vacuoles" unless they are accompanied by other toxic changes, as vacuolation can occur in other conditions.
=== Drugs of abuse === Synthetic cannabinoids Cocaine LSD Opiates (e.g., fentanyl, oxycodone, heroin, codeine, and morphine) Amphetamines (e.g., MDMA (Ecstasy), MDA, Meth) "Bath salts" (e.g., cathinone, synthetic cathinone, MDPV) GHB Phencyclidine (PCP)
Sources: en.wikipedia.org
=== Rotigotine === Rotigotine (sold under the brand name Neupro, among others) is a dopamine agonist indicated for the treatment of Parkinson's disease (PD) and restless legs syndrome (RLS). In 2007, the Neupro patch was approved by the Food and Drug Administration (FDA) as the first transdermal patch treatment of Parkinson's disease in the United States. The drug had been established in 1980, and no prior polymorphism had been observed. In 2008, a more stable polymorph unexpectedly emerged, which was described as resembling "snow-like crystals". The new polymorph did not display any observable reduction in efficacy, but nonetheless, Schwarz Pharma recalled all Neupro patches in the United States and some in Europe. Those with remaining patches in Europe were told to refrigerate their stock, since refrigeration seemed to reduce crystallization rates. The patch was reformulated in 2012, as per FDA recommendations, and was reintroduced in the United States without requiring refrigeration.
=== Base-pairing === Canonical bases may have either a carbonyl or an amine group on the carbons surrounding the nitrogen atom furthest away from the glycosidic bond, which allows them to base pair (Watson-Crick base pairing) via hydrogen bonds (amine with ketone, purine with pyrimidine). Adenine and 2-aminoadenine have one/two amine group(s), whereas thymine has two carbonyl groups, and cytosine and guanine are mixed amine and carbonyl (inverted in respect to each other).
Jaw joint – The dentary (the lower jaw bone, which carries the teeth) and the squamosal (a small cranial bone) meet to form the joint. In most gnathostomes, including early therapsids, the joint consists of the articular (a small bone at the back of the lower jaw) and quadrate (a small bone at the back of the upper jaw). Middle ear – In crown-group mammals, sound is carried from the eardrum by a chain of three bones, the malleus, the incus and the stapes. Ancestrally, the malleus and the incus are derived from the articular and the quadrate bones that constituted the jaw joint of early therapsids. Tooth replacement – Teeth can be replaced once (diphyodonty) or (as in toothed whales and murid rodents) not at all (monophyodonty). Elephants, manatees, and kangaroos continually grow new teeth throughout their life (polyphyodonty). Prismatic enamel – The enamel coating on the surface of a tooth consists of prisms, solid, rod-like structures extending from the dentin to the tooth's surface. Occipital condyles – Two knobs at the base of the skull fit into the topmost neck vertebra; most other tetrapods, in contrast, have only one such knob. For the most part, these characteristics were not present in the Triassic ancestors of the mammals. Nearly all mammaliaforms possess an epipubic bone, the exception being modern placentals.
Barker often appeared in fiction as himself, usually in a cameo appearance, in shows including The Nanny, The Bold and the Beautiful Futurama, and How I Met Your Mother.In 1996, Barker played himself in the Adam Sandler comedy Happy Gilmore. In one scene, Barker beats up Gilmore after an altercation arising from their teaming up in a Pro-Am Golf Tournament. According to Sandler, the original choice for that scene was Ed McMahon, but Sandler said that McMahon was not fond of the script and they got Barker because of Chuck Norris training Barker in the martial arts. Barker also played himself in the animated series Family Guy, starting in 2001 with the episode "Screwed the Pooch" with his last appearance being in 2008 in the episode "Tales of a Third Grade Nothing". In 2007, during a CBS prime-time special commemorating Barker's career, the fight scene from Happy Gilmore was shown, after which Sandler made a surprise appearance on stage to read a poem paying tribute to Barker. In 2015, during Comedy Central's "Night of Too Many Stars" benefit show to battle autism, Barker and Sandler reunited for a video featuring the two of them in a follow-up fight at the hospital, which ends with both of them dying and going to heaven. However, Barker did play characters apart from himself in Bonanza, as a character named Mort in the 1960 episode "Denver McKee", and as a small business owner named Bob Barnacle in "Sanctuary!", an episode of the Nickelodeon animated series SpongeBob SquarePants.
Twenty isotopes and six nuclear isomers (excited states of an isotope) of berkelium have been characterized, with mass numbers ranging from 233 to 253 (except 237). All of them are radioactive. The longest half-lives are observed for 247Bk (1,380 years), 248Bk (unknown, almost surely over 300 years), and 249Bk (327.2 days); other isotopes are less than a week. The isotope which is the easiest to synthesize (reactor neutron capture) is berkelium-249. This emits mostly soft β-particles which are inconvenient for detection. Its alpha radiation is rather weak (1.45×10−3%) with respect to the β-radiation, but is sometimes used to detect this isotope. The second important berkelium isotope, berkelium-247, is beta-stable and an alpha emitter, as are most long-lived actinide isotopes.
Sources: en.wikipedia.org
It mimics a natural hypothalamic signal that tells the pituitary to release growth hormone. The result is a rise in circulating growth hormone and, indirectly, in insulin-like growth factor 1. Over weeks of treatment this shift is associated with a selective decrease in fat stored inside the abdomen.
The primary measure is usually a cross-sectional abdominal scan that separates internal fat from fat just under the skin. Waist circumference and body weight are recorded as secondary measures because they are easy to obtain but do not distinguish the two fat compartments. Hormone and metabolic blood tests are collected alongside the imaging.
Available follow-up data indicate that visceral fat drifts back toward pretreatment levels once injections stop. The change is therefore best described as treatment-dependent rather than permanent. Investigators continue to debate whether intermittent or repeated courses would preserve any benefit.
It is a synthetic peptide analog of human growth hormone-releasing hormone. It is used clinically to reduce excess visceral abdominal fat in adults with HIV-associated lipodystrophy. It works by stimulating pituitary growth hormone release.